A PHASE 1/2 TRIAL OF FOG-001, A FIRST-INCLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA (ACP) PATIENTS

Authors
Category Primary study
Conference7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, WFNOS and 30th Society for Neuro-Oncology Annual Meeting, SNO
Year 2025
This article has no abstract
Epistemonikos ID: f621d9c5f4e0f305faeff3923e1c8f1a53b4c949
First added on: Dec 12, 2025